Daewoong Pharma (069620) — Cash Flow-to-Debt Ratio
Daewoong Pharma (069620) has a Cash Flow-to-Debt Ratio of 0.05x as of September 2025, meaning its operating cash flow of ₩57.53 Billion could theoretically repay 0% of its total liabilities (₩1.26 Trillion) in one year. Explore Daewoong Pharma strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Daewoong Pharma Cash Flow-to-Debt Ratio (2007–2024)
Historical debt coverage capacity for Daewoong Pharma across 16 annual periods. Also explore balance sheet size of Daewoong Pharma for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Daewoong Pharma (2007–2024)
Year-by-year debt coverage analysis for Daewoong Pharma. For market capitalisation and broader financial context, see Daewoong Pharma stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.05x | ₩51.49 Billion | ₩1.05 Trillion | ▼ -71.8% |
| 2023 | 0.17x | ₩132.57 Billion | ₩762.77 Billion | ▲ +20.9% |
| 2022 | 0.14x | ₩118.21 Billion | ₩822.12 Billion | ▲ +156.3% |
| 2021 | 0.06x | ₩39.99 Billion | ₩712.77 Billion | ▼ -62.7% |
| 2020 | 0.15x | ₩100.98 Billion | ₩671.66 Billion | ▲ +59.2% |
| 2019 | 0.09x | ₩57.60 Billion | ₩609.75 Billion | ▲ +19.3% |
| 2018 | 0.08x | ₩47.50 Billion | ₩600.04 Billion | ▼ -55.7% |
| 2017 | 0.18x | ₩103.94 Billion | ₩581.99 Billion | ▲ +527.3% |
| 2016 | 0.03x | ₩15.38 Billion | ₩540.15 Billion | ▼ -71.1% |
| 2015 | 0.10x | ₩35.89 Billion | ₩364.29 Billion | ▼ -9.3% |
| 2014 | 0.11x | ₩25.95 Billion | ₩238.76 Billion | ▼ -71.7% |
| 2013 | 0.38x | ₩54.16 Billion | ₩141.05 Billion | ▼ -18.3% |
| 2012 | 0.47x | ₩45.02 Billion | ₩95.76 Billion | ▼ -18.8% |
| 2011 | 0.58x | ₩78.82 Billion | ₩136.04 Billion | ▲ +283.6% |
| 2008 | 0.15x | ₩31.33 Billion | ₩207.39 Billion | ▼ -27.9% |
| 2007 | 0.21x | ₩25.81 Billion | ₩123.24 Billion | — |